Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction

James L Slack, W. Bi, K. J. Livak, N. Beaubier, M. Yu, M. Clark, S. H. Kim, R. E. Gallagher, C. L. Willman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We have developed a sensitive and quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay for detection of PML-RARα, the fusion oncogene present as a specific marker in >99% of cases of acute promyelocytic leukemia (APL). The assay is linear over at least 5 orders of magnitude of input DNA or RNA, and detects as few as 4 copies of PML-RARα plasmid DNA. PML-RARα transcripts could be detected in mixtures containing 2 to 5 pg of RNA from fusion-containing cells in a background of 1 μg of RNA from PML-RARα-negative cells. Using 1.0 to 2.5 μg of input RNA, the sensitivity of the assay was between 10-5 and 10-6. Furthermore, determination of GAPDH copy number in each reaction allowed an accurate assessment of sample-to-sample variation in RNA quality and reaction efficiency, with consequent definition of a detection limit for each sample assayed. Using an internal calibrator, assay precision was high, with coefficients of variation between 10 and 20%. An interlaboratory study using coded samples demonstrated excellent reproducibility and high concordance between laboratories. This assay will be used to test the hypothesis that sensitive and quantitative measurement of leukemic burden, during or after therapy of APL, can stratify patients into discrete risk groups, and thereby serve as a basis for risk-adapted therapy in APL.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalJournal of Molecular Diagnostics
Volume3
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Reverse Transcription
Acute Promyelocytic Leukemia
RNA
Polymerase Chain Reaction
Messenger RNA
Oncogene Fusion
Cell Fusion
DNA
Limit of Detection
Plasmids
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction. / Slack, James L; Bi, W.; Livak, K. J.; Beaubier, N.; Yu, M.; Clark, M.; Kim, S. H.; Gallagher, R. E.; Willman, C. L.

In: Journal of Molecular Diagnostics, Vol. 3, No. 4, 2001, p. 141-149.

Research output: Contribution to journalArticle

Slack, JL, Bi, W, Livak, KJ, Beaubier, N, Yu, M, Clark, M, Kim, SH, Gallagher, RE & Willman, CL 2001, 'Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction', Journal of Molecular Diagnostics, vol. 3, no. 4, pp. 141-149.
Slack, James L ; Bi, W. ; Livak, K. J. ; Beaubier, N. ; Yu, M. ; Clark, M. ; Kim, S. H. ; Gallagher, R. E. ; Willman, C. L. / Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction. In: Journal of Molecular Diagnostics. 2001 ; Vol. 3, No. 4. pp. 141-149.
@article{d93d393233d940f894275ad378091947,
title = "Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction",
abstract = "We have developed a sensitive and quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay for detection of PML-RARα, the fusion oncogene present as a specific marker in >99{\%} of cases of acute promyelocytic leukemia (APL). The assay is linear over at least 5 orders of magnitude of input DNA or RNA, and detects as few as 4 copies of PML-RARα plasmid DNA. PML-RARα transcripts could be detected in mixtures containing 2 to 5 pg of RNA from fusion-containing cells in a background of 1 μg of RNA from PML-RARα-negative cells. Using 1.0 to 2.5 μg of input RNA, the sensitivity of the assay was between 10-5 and 10-6. Furthermore, determination of GAPDH copy number in each reaction allowed an accurate assessment of sample-to-sample variation in RNA quality and reaction efficiency, with consequent definition of a detection limit for each sample assayed. Using an internal calibrator, assay precision was high, with coefficients of variation between 10 and 20{\%}. An interlaboratory study using coded samples demonstrated excellent reproducibility and high concordance between laboratories. This assay will be used to test the hypothesis that sensitive and quantitative measurement of leukemic burden, during or after therapy of APL, can stratify patients into discrete risk groups, and thereby serve as a basis for risk-adapted therapy in APL.",
author = "Slack, {James L} and W. Bi and Livak, {K. J.} and N. Beaubier and M. Yu and M. Clark and Kim, {S. H.} and Gallagher, {R. E.} and Willman, {C. L.}",
year = "2001",
language = "English (US)",
volume = "3",
pages = "141--149",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "4",

}

TY - JOUR

T1 - Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription polymerase chain reaction

AU - Slack, James L

AU - Bi, W.

AU - Livak, K. J.

AU - Beaubier, N.

AU - Yu, M.

AU - Clark, M.

AU - Kim, S. H.

AU - Gallagher, R. E.

AU - Willman, C. L.

PY - 2001

Y1 - 2001

N2 - We have developed a sensitive and quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay for detection of PML-RARα, the fusion oncogene present as a specific marker in >99% of cases of acute promyelocytic leukemia (APL). The assay is linear over at least 5 orders of magnitude of input DNA or RNA, and detects as few as 4 copies of PML-RARα plasmid DNA. PML-RARα transcripts could be detected in mixtures containing 2 to 5 pg of RNA from fusion-containing cells in a background of 1 μg of RNA from PML-RARα-negative cells. Using 1.0 to 2.5 μg of input RNA, the sensitivity of the assay was between 10-5 and 10-6. Furthermore, determination of GAPDH copy number in each reaction allowed an accurate assessment of sample-to-sample variation in RNA quality and reaction efficiency, with consequent definition of a detection limit for each sample assayed. Using an internal calibrator, assay precision was high, with coefficients of variation between 10 and 20%. An interlaboratory study using coded samples demonstrated excellent reproducibility and high concordance between laboratories. This assay will be used to test the hypothesis that sensitive and quantitative measurement of leukemic burden, during or after therapy of APL, can stratify patients into discrete risk groups, and thereby serve as a basis for risk-adapted therapy in APL.

AB - We have developed a sensitive and quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay for detection of PML-RARα, the fusion oncogene present as a specific marker in >99% of cases of acute promyelocytic leukemia (APL). The assay is linear over at least 5 orders of magnitude of input DNA or RNA, and detects as few as 4 copies of PML-RARα plasmid DNA. PML-RARα transcripts could be detected in mixtures containing 2 to 5 pg of RNA from fusion-containing cells in a background of 1 μg of RNA from PML-RARα-negative cells. Using 1.0 to 2.5 μg of input RNA, the sensitivity of the assay was between 10-5 and 10-6. Furthermore, determination of GAPDH copy number in each reaction allowed an accurate assessment of sample-to-sample variation in RNA quality and reaction efficiency, with consequent definition of a detection limit for each sample assayed. Using an internal calibrator, assay precision was high, with coefficients of variation between 10 and 20%. An interlaboratory study using coded samples demonstrated excellent reproducibility and high concordance between laboratories. This assay will be used to test the hypothesis that sensitive and quantitative measurement of leukemic burden, during or after therapy of APL, can stratify patients into discrete risk groups, and thereby serve as a basis for risk-adapted therapy in APL.

UR - http://www.scopus.com/inward/record.url?scp=0035189081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035189081&partnerID=8YFLogxK

M3 - Article

C2 - 11687597

AN - SCOPUS:0035189081

VL - 3

SP - 141

EP - 149

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 4

ER -